Evaluation of 18F-AlF-NOTA-octreotide for imaging neuroendocrine neoplasms: comparison with 68Ga-DOTATATE PET/CT

被引：22
作者：
Hou, Jiale [1 ]
Long, Tingting [1 ]
He, Zhiyou [1 ]
Zhou, Ming [1 ]
Yang, Nengan [1 ]
Chen, Dengming [1 ]
Zeng, Shan [2 ]
Hu, Shuo [1 ,3 ,4 ]
机构：
[1] Cent South Univ, XiangYa Hosp, Dept Nucl Med, 87 XiangYa Rd, Changsha, Hunan, Peoples R China
[2] Cent South Univ, XiangYa Hosp, Dept Canc Chemotherapy, 87 XiangYa Rd, Changsha, Hunan, Peoples R China
[3] Key Lab Biol Nanotechnol, NHC 87 XiangYa Rd, Changsha 410013, Hunan, Peoples R China
[4] XiangYa Cent South Univ, Natl Clin Res Ctr Geriatr Disorders XIANGYA, Changsha 410008, Hunan, Peoples R China
来源：
EJNMMI RESEARCH | 2021年 / 11卷 / 01期
基金：
中国国家自然科学基金;
关键词：
TUMORS;
D O I：
10.1186/s13550-021-00797-4
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Objective: To evaluate the diagnostic efficacy of F-18-AlF-NOTA-octreotide (F-18-OC) PET/CT compared with that of Ga-68-DOTATATE PET/CT. Materials and methods: Twenty patients (mean age: 52.65 years, range: 24-70 years) with biopsy-proven neuroendocrine neoplasms (NENs) were enrolled in this prospective study. We compared the biodistribution profiles in normal organs based on the maximum standard uptake value (SUVmax) and mean standard uptake value (SUVmean), and uptake in NEN lesions by measuring the SUVmax on F-18-OC and Ga-68-DOTATATE PET/CT images. The tumor-to-liver ratio (TLR) and tumor-to-spleen ratio were calculated by dividing the SUVmax of different tumor lesions by the SUVmean of the liver and spleen, respectively. The Wilcoxon signed-rank test was used to compare nonparametric data. Data were expressed as the median (interquartile range). Results: In most organs, there were no significant differences in the biodistribution of Ga-68-DOTATATE and F-18-OC. F-18-OC had significantly lower uptake in the salivary glands and liver than Ga-68-DOTATATE. F-18-OC detected more lesions than Ga-68-DOTATATE. Theuptake of F-18-OC in the tumors was higher in most patients, but the difference was not statistically significant relative to that of Ga-68-DOTATATE. However, the TLRs of F-18-OC were higher in most patients, including for lesions in the liver (p = 0.02) and lymph nodes (p = 0.02). Conclusion: Relative to Ga-68-DOTATATE, F-18-OC possesses favorable characteristics with similar image quality and satisfactory NEN lesion detection rates, especially in the liver due to its low background uptake. F-18-OC therefore offers a promising clinical alternative for Ga-68-DOTATATE.
引用
收藏
页数：9
相关论文
共 19 条
[1]   Clinical applications of Gallium-68 [J].
Banerjee, Sangeeta Ray ;
Pomper, Martin G. .
APPLIED RADIATION AND ISOTOPES, 2013, 76 :2-13
[2]   False-positive findings on 6-[18F]fluor-L-3,4-dihydroxyphenylalanine PET (18F-FDOPA-PET) performed for imaging of neuroendocrine tumors [J].
Berends, Annika M. A. ;
Kerstens, Michiel N. ;
Bolt, Janne W. ;
Links, Thera P. ;
Korpershoek, Esther ;
de Krijger, Ronald R. ;
Walenkamp, Annemiek M. E. ;
Noordzij, Walter ;
van Etten, Boudewijn ;
Kats-Ugurlu, Gursah ;
Brouwers, Adrienne H. ;
van der Horst-Schrivers, Anouk N. A. .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2018, 179 (02) :125-133
[3]   Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA [J].
Bozkurt, Murat Fani ;
Virgolini, Irene ;
Balogova, Sona ;
Beheshti, Mohsen ;
Rubello, Domenico ;
Decristoforo, Clemens ;
Ambrosini, Valentina ;
Kjaer, Andreas ;
Delgado-Bolton, Roberto ;
Kunikowska, Jolanta ;
Oyen, Wim J. G. ;
Chiti, Arturo ;
Giammarile, Francesco ;
Fanti, Stefano .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (09) :1588-1601
[4]   Fluorine-18 radiopharmaceuticals beyond [18F]FDG for use in oncology and neurosciences [J].
Coenen, H. H. ;
Elsinga, P. H. ;
Iwata, R. ;
Kilbourn, M. R. ;
Pillai, M. R. A. ;
Rajan, M. G. R. ;
Wagner, H. N., Jr. ;
Zaknun, J. J. .
NUCLEAR MEDICINE AND BIOLOGY, 2010, 37 (07) :727-740
[5]   Physics of pure and non-pure positron emitters for PET: a review and a discussion [J].
Conti, Maurizio ;
Eriksson, Lars .
EJNMMI PHYSICS, 2016, 3 (01)
[6]   Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States [J].
Dasari, Arvind ;
Shen, Chan ;
Halperin, Daniel ;
Zhao, Bo ;
Zhou, Shouhao ;
Xu, Ying ;
Shih, Tina ;
Yao, James C. .
JAMA ONCOLOGY, 2017, 3 (10) :1335-1342
[7]   Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors [J].
Hope, Thomas A. ;
Bergsland, Emily K. ;
Bozkurt, Murat Fani ;
Graham, Michael ;
Heaney, Anthony P. ;
Herrmann, Ken ;
Howe, James R. ;
Kulke, Matthew H. ;
Kunz, Pamela L. ;
Mailman, Josh ;
May, Lawrence ;
Metz, David C. ;
Millo, Corina ;
O'Dorisio, Sue ;
Reidy-Lagunes, Diane L. ;
Soulen, Michael C. ;
Strosberg, Jonathan R. .
JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (01) :66-74
[8]   Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors [J].
Ilhan, Harun ;
Lindner, S. ;
Todica, A. ;
Cyran, C. C. ;
Tiling, R. ;
Auernhammer, C. J. ;
Spitzweg, C. ;
Boeck, S. ;
Unterrainer, M. ;
Gildehaus, F. J. ;
Boening, G. ;
Jurkschat, K. ;
Waengler, C. ;
Waengler, B. ;
Schirrmacher, R. ;
Bartenstein, P. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (04) :870-880
[9]   PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature [J].
Johnbeck, Camilla Bardram ;
Knigge, Ulrich ;
Kjaer, Andreas .
FUTURE ONCOLOGY, 2014, 10 (14) :2259-2277
[10]   68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT [J].
Kroiss, A. ;
Putzer, D. ;
Decristoforo, C. ;
Uprimny, C. ;
Warwitz, B. ;
Nilica, B. ;
Gabriel, M. ;
Kendler, D. ;
Waitz, D. ;
Widmann, G. ;
Virgolini, I. J. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (04) :514-523
12